Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice

Cancer Immunology, Immunotherapy

Volumn 54, Issue 4, 2005, Pages 345-350

  Johnston, Dean ^a   Bystryn, Jean Claude ^b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heterogeneous antibody response; Murine model; Polyvalent cancer vaccines

Indexed keywords

IMMUNOGLOBULIN G; MELANOMA VACCINE;

ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; IMMUNIZATION; IMMUNOGENICITY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CANCER VACCINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MELANOMA; MICE; MICE, INBRED BALB C; MOLECULAR WEIGHT; SKIN NEOPLASMS;

EID: 13744258176     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0606-9     Document Type: Article

References (17)

1. Bystryn J-C, Shapiro RL, Oratz R (1995) Cancer vaccines: clinical applications: partially purified tumor antigen vaccines. In: DeVita V, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer, 2nd edn. Lippincott, Philadelphia, pp 668-679
2. Bystryn J-C, Oratz R, Shapiro RL, Harris MN, Roses DF, Zeleniuch-Jacquotte A, Chen DL, Rivas MC (1999) Double-blind, placebo-controlled trial of a shed, polyvalent, melanoma vaccine in stage III melanoma. Proc Am Soc Clin Oncol 434:1673
3. DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O'Day SJ, Wanek LA, Stern SL, Morton DL (2002) Enhanced humoral immune response correlates with improved disease-free and overall survival in American joint committee on cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 20:3242-3248
4. Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 8:630-641
5. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA, Davoust J, Miconnet I, Vonderheide RH, Kosmatopoulos K (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425-433
6. Hsueh EC, Essner R, Foshag LJ, Ye W, Morton DL (2002) Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma. Ann Surg Oncol 5:486-492
7. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the society for biological therapy. J Immunother 15:97-138
8. Livingston P (2001) The unfulfilled promise of melanoma vaccines. Clin Cancer Res 7:1837-1838
9. Miller K, Abeles G, Oratz R, Zeleniuch-Jacquotte A, Cui J, Roses DF, Harris M, Bystryn J-C (1995) Improved survival of melanoma patients with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75(2):495-502
10. Reynolds SR, Oratz R, Shapiro RL, Fotino M, Hao P, Vukmanovic S, Bystryn J-C (1997) Stimulation of CD8+ T cell responses to MAGE-3 and MELAN A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer 72:1-5
11. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn J-C (1998) HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan A/MART-1, gp100, tyrosinase, MC1R and TRP-2 in vaccine-treated melanoma patients. J Immunol 161:6970-6976
12. Shapiro RL, Johnston D, Oratz R, Harris MN, Roses DF, Zeleniuch-Jacquotte A, Beck A, Bystryn J-C (1999) Effect of GM-CSF liposomes on the immunogenicity of a polyvalent melanoma vaccine. Proc Am Soc Clin Oncol 440:1695
13. Shen HD, Choo KB, Lin WL, Lin RY, Han SH (1990) An improved scheme for the identification of antigens recognized by specific antibodies in two-dimensional gel electrophoresis and immunoblotting. Electrophoresis 11:878-882
14. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbits S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EMH, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH (2003) Clinical and immunological results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21:4016-4026
15. Sosman JA, Weeraratna AT, Sondak VK (2004) When will melanoma vaccines be proven effective? J Clin Oncol 22:1-3
16. Tjoa BA, Elgamal A-AA, Murphy GP (1999) Vaccine therapy for prostate cancer. Urol Clin North Am 26(2):365-374
17. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO (1998) Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Can Res 4:295-302